Intra-Cellular Therapies (ITCI +10%) perks up on modestly higher volume ahead of a presentation of lumateperone data tomorrow at the American College of Neuropsychopharmacology Annual Meeting in Hollywood, FL.
Results from a Phase 3 study in bipolar depression, pooled data in schizophrenia and results from a 12-month safety study will be presented at 5:30 pm ET.
The FDA’s action date for the company’s application seeking approval of lumateperone for schizophrenia is Friday, December 27.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.